文献速递眼底病与葡萄膜炎

手术、组织型纤溶酶原激活剂、抗血管生成药物与年龄相关性黄斑变性研究:针对年龄相关性黄斑变性继发黄斑下出血的随机对照试验

Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2023-04-22

这项随机、开放标签、多中心优效性研究纳入90例50岁及以上、近期(≤14天)发生黄斑下出血(SMH)且出血面积大于2个视盘面积、主要覆盖视网膜色素上皮的nAMD患者,比较玻璃体切割术(PPV)联合视网膜下tPA与气体填充 vs 气动置换(PD)联合玻璃体内tPA与气体填充,两组均加用玻璃体内雷珠单抗。主要终点为第3个月平均最佳矫正视力(BCVA)变化,手术组+16.8字母 vs PD组+16.4字母,未达显著优效(P=0.767)。结论认为手术并未优于PD,两种策略均带来视力临床改善且6个月内无安全性顾虑,但试验设计及结果不能用于确立两种治疗的等效性。

要点

  • 手术组第3个月BCVA平均提升+16.8字母,PD组+16.4字母,组间差异未达统计学显著(P=0.767)。
  • 两组第6个月次要结局相似,均未观察到非预期眼部安全性问题。
  • 作者结论:手术未较PD带来更优视力获益,但本试验不能用于确立两种治疗等效。

核心结论

  • 对于nAMD继发SMH,联合玻璃体内抗VEGF治疗时,手术在第3个月未较PD带来更优视力获益或额外获益。
  • 两种治疗策略在6个月内均带来视力临床改善且无安全性顾虑。
  • 本试验的设计与结果不能用于确立两种治疗间的等效性。

研究设计与样本

  • 随机、开放标签、多中心优效性研究,共纳入90例50岁及以上、近期(≤14天)SMH面积大于2个视盘面积且主要覆盖视网膜色素上皮的nAMD患者。
  • 患者随机分配至手术组(PPV、视网膜下tPA最大0.5 ml/50 μg、20%六氟化硫填充)或PD组(玻璃体内tPA 0.05 ml/50 μg、玻璃体内纯六氟化硫0.3 ml)。
  • 两组干预后均要求保持头正位、面部朝前45°位3天,并在干预结束时、第1和第2个月接受0.5 mg玻璃体内雷珠单抗负荷治疗,随后6个月随访期间按需给药。

主要发现

  • 90例随机患者中78例(86.7%)完成第3个月疗效终点访视。
  • 手术组从基线至第3个月平均BCVA变化为+16.8字母(95%CI 8.7-24.9字母),PD组为+16.4字母(95%CI 7.1-25.7字母),校正后差异β=1.9(-11.0至14.9),P=0.767,手术组未显著优于PD组。
  • 两组第6个月次要结局相似,包括平均BCVA变化、第3和第6个月25项美国国家眼科研究所视觉功能问卷综合评分、抗VEGF注射次数及6个月随访期间并发症。
  • 两组均未观察到非预期眼部安全性问题。

临床怎么用

  • 原文结论指出,对于nAMD继发SMH,在联合玻璃体内抗VEGF治疗时,手术未较PD带来更优视力获益或额外获益(作者结论)。
  • 原文结论指出,两种治疗策略在6个月内均带来视力临床改善且无安全性顾虑(作者结论)。
  • 原文结论指出,本试验的设计与结果不能用于确立两种治疗间的等效性(作者结论)。

局限性

  • 原文结论指出,本试验的设计与结果不能用于确立两种治疗间的等效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy and the safety of submacular hemorrhage (SMH) management using either surgical pars plana vitrectomy (PPV) or pneumatic displacement (PD) with tissue plasminogen activator (tPA) and vascular endothelial growth factor (VEGF) inhibitor added to each arm. DESIGN: Randomized, open-label, multicenter superiority study. PARTICIPANTS: Ninety patients with neovascular age-related macular degeneration (nAMD) 50 years of age or older with recent SMH (≤ 14 days) of more than 2 optic disc areas and predominantly overlying the retinal pigment epithelium. METHODS: Patients were assigned randomly to surgery (PPV, subretinal tPA [maximum, 0.5 ml/50 μg], and 20% sulfur hexafluoride [SF6] tamponade) or PD (0.05 ml intravitreal tPA [50 μg] and 0.3 ml intravitreal pure SF6). Both groups were asked to maintain a head upright position with the face forward at 45° for 3 days after intervention and received 0.5 mg intravitreal ranibizumab at the end of the intervention, at months 1 and 2, as the loading phase, and then on a pro re nata regimen during a 6-month follow-up. MAIN OUTCOME MEASURES: The primary efficacy endpoint was mean best-corrected visual acuity (VA) change at month 3. The secondary endpoints were mean VA change at month 6, 25-item National Eye Institute Visual Function Questionnaire composite score value at months 3 and 6, number of anti-VEGF injections, and complications during the 6-month follow-up. RESULTS: Of the 90 patients randomized, 78 patients (86.7%) completed the 3-month efficacy endpoint visit. The mean VA change from baseline to month 3 in the surgery group (+16.8 letters [95% confidence interval (CI), 8.7-24.9 letters]) was not significantly superior to that in the PD group (+16.4 letters [95% CI, 7.1-25.7 letters]; adjusted difference β, 1.9 [-11.0; 14.9]; P = 0.767). Both groups achieved similar secondary outcomes at month 6. No unexpected ocular safety concerns were observed in either group. CONCLUSIONS: Surgery did not yield superior visual gain nor additional benefit for SMH secondary to nAMD compared with PD at 3 months, with intravitreal anti-VEGF added to each arm. Both treatment strategies lead to a clinical improvement of VA without safety concerns for SMH over 6 months. Both design and results of the trial cannot be used to establish equivalence between treatments. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Gabrielle PH, Delyfer MN, Glacet-Bernard A, et al. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration. Ophthalmology. 2023. PMID: 37088447. doi:10.1016/j.ophtha.2023.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。